HR Execs on the Move

Stallergenes Greer

www.stallergenesgreer.com

 
Stallergenes Greer is a global biopharmaceutical company specializing in the diagnosis and treatment of respiratory allergies through the development and commercialization of Allergy Immunotherapy products and services. Our purpose is to enable people with allergies to live normal lives. With more than 1,400 employees worldwide, a presence in 75 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France). With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Dey Pharmaceuticals

Dey Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Broadstep

CompassionWe embrace each persons’ journey, celebrating unique perspectives and situations free of judgment.TeamworkWe are one team. We celebrate each others’ successes and work together to overcome challenges.ExcellenceWe grow with each other, so we p...

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.

Viking Therapeutics

Novel therapeutics for metabolic and endocrine disorders

Macrolide Pharmaceuticals

Macrolide Pharmaceuticals is a next-generation antibiotics company developing macrolides that are first-in-class with Gram-negative activity and will have broad applicability across multiple resistant infectious diseases.